

VICE PRESIDENT
MICHAEL VON KORFF, SCD
SEATTLE, WA

ROSEMARY ORR, MD SEATTLE, WA

SECRETARY STEPHEN GELFAND, MD MYRTLE BEACH, SC

JANE BALLANTYNE, MD
SEATTLE, WA

IRFAN DHALLA, MD, MSC

GARY FRANKLIN, MD, MPH SEATTLE, WA

PETE JACKSO ARLINGTON HEIGHTS,

DAVID JUURLINK, MD, PHD

PETROS LEVOUNIS, MD, MA

LEN PAULOZZI, MD, MPH

BETTS TULLY CHICAGO, IL

ART VAN ZEE, MD

PHYSICIANS FOR RESPONSIBLE OPIOID PRESCRIBING

Dockets Management Branch Food and Drug Administration Room 1061 5630 Fishers Lane Rockville MD 20852

July 25, 2012

The undersigned clinicians, researchers and health officials from fields that include Pain, Addiction, Primary Care, Internal Medicine, Anesthesiology, Psychiatry, Neurology, Emergency Medicine, Toxicology, Rheumatology, and Pubic Health submit this petition under Section 21 CFR 10.20 and 21 CFR 10.30 and other pertinent sections of the Federal Food, Drug and Cosmetic Act or any other statutory provision which authority has been delegated to the FDA Commissioner to regulate labeling of opioid analgesics.

At present, the FDA-approved indication for nearly all instant-release opioid analysesics is "moderate to severe pain". For extended-release opioids, the indication is for "moderate to severe pain when a continuous, around-the clock analgesic is needed for an extended period of time." These overly broad indications imply a determination by FDA that they are safe and effective for long-term use. As outlined below, an increasing body of medical literature suggests that long-term use of opioids may be neither safe nor effective for many patients, especially when prescribed in high doses.

Unfortunately, many clinicians are under the false impression that chronic opioid therapy (COT) is an evidence-based treatment for chronic non-cancer pain (CNCP) and that dose-related toxicities can be avoided by slow upward titration. These misperceptions lead to over-prescribing and high dose prescribing. By implementing the label changes proposed in this petition, FDA has an opportunity to reduce harm caused to chronic pain patients as well as societal harm caused by diversion of prescribed opioids. In addition, FDA will be able to reinforce adherence to dosing limits that have been recommended by the United States Centers for Disease Control¹, the state of Washington² and the New York City Department of Health and Mental Hygiene³.

The Federal Food, Drug and Cosmetic Act established that a drug intended to treat a condition must be proven safe and effective for use as labeled. The current label on opioid analgesics does not comply with this law. By taking the actions requested in this petition, FDA will be able to exercise its regulatory responsibility over opioid manufacturers by prohibiting the marketing of opioids for conditions in which their use has not been proven safe and effective.

Office: 718.283.7557

SPECIFIC ACTIONS REQUESTED FOR CHANGES TO OPIOID ANALGESIC LABELS:

- 1. Strike the term "moderate" from the indication for non-cancer pain.
- 2. Add a maximum daily dose, equivalent to 100 milligrams of morphine for non-cancer pain.
- 3. Add a maximum duration of 90-days for continuous (daily) use for non-cancer pain.

STATEMENTS OF SCIENTIFIC BASIS FOR PETITION:

- 1. Over the past decade, a four-fold increase in prescribing of opioid analgesics has been associated with a four-fold increase in opioid related overdose deaths and a six-fold increase in individuals seeking treatment for addiction to opioid analgesics.⁵
- 2. Prescribing of opioids increased over the past 15 years in response to a campaign that minimized risks of long-term use for CNCP and exaggerated benefits. ^{6,7,8}
- 3. Long-term safety and effectiveness of managing CNCP with opioids has not been established.⁹
- 4. Recent surveys of CNCP patients receiving COT have shown that many continue to experience significant chronic pain and dysfunction. 10,11
- 5. Recent surveys using DSM criteria found high rates of addiction in CNCP patients receiving COT. 12,13
- 6. A large sample of medical and pharmacy claims records found that two-thirds of patients who took opioids on a daily basis for 90 days were still taking opioids five years later.¹⁴
- 7. Patients with mental health and substance abuse co-morbidities are more likely to receive COT than patients who lack these risk factors, a phenomenon referred to as *adverse selection*.¹⁵
- 8. Three large observational studies published in 2010 and 2011 found dose-related overdose risk in CNCP patients on COT. 16,17,18
- 9. COT at high doses is associated with increased risk of overdose death¹⁸, emergency room visits¹⁹ and fractures in the elderly²⁰.

There is no environmental impact associated with this Citizen's Petition and we wish to be excluded under 21 CFR Sec. 25.24.

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petition which are unfavorable to the petition (21 CFR Sec.10.30b).

Jane C. Ballantyne, MD. FRCA UW Professor of Education and Research Department of Anesthesiology and Pain Medicine Seattle, Washington

Medical Director, Emergency Department Swedish Cherry Hill Medical Center Seattle, Washington

Edward C. Covington, MD

Director, Neurological Center for Pain

Cleveland Clinic Cleveland, Ohio

Kaiser Permanente Professor of Evidence-Based Family Medicine, Dept. of Family Medicine Department of Medicine Director, OCTRI Community and Practice Research Program Oregon Health and Science University

Thomas A. Farley, MD, MPH Commissioner, Department of Health City of New York

Stephen G. Gelfand, MD. FACP

Secretary, Physicians for Responsible Opioid

Prescribing

Myrtle Beach, South Carolina

Medical Director, Fairview Pain Center Adjunct Professor, Department of Neurology, University of Minnesota Medical Center Minneapolis, Minnesota

Associate Professor of Medicine Dept. of Medicine and Dept. of Medical Informatics and Clinical Epidemiology Oregon Health & Science University

Robert W. Day, MD, PhD

President Emeritus

Fred Hutchinson Cancer Research Center Seattle, Washington

Irfan Dhalla, MD, MSc

Assistant Professor, University of Toronto

Toronto, Ontario

Gary M. Franklin, MD, MPH

Research Professor, University of Washington Director, Occupational Epidemiology and Health Outcomes Program

Seattle, Washington

Stuart Citlow, MD, MBA, MPH, FAPA

Acting President

American Society of Addiction Medicine

Chevy Chase, Maryland

Roland W. Gray, MD, FASAM

Medical Director, Tennessee Medical Foundation Physician's Health Program Brentwood, Tennessee Erik Gunderson, MD, FASAM

Assistant Professor, Dept. of Psychiatry & Neurobehavioral Sciences and Dept. of Medicine Director, Clinical Pharmacological Research Unit University of Virginia

W. Michael Hooten, MD.

Associate Professor of Anesthesiology

Mayo Clinic

Rochester, Minnesota

Head, Division of Clinical Pharmacology and Toxicology, University of Toronto

Toronto, Ontario

Andrew Kolodny, MD

President, Physicians for Responsible Opioid Prescribing; Chair, Dept. of Psychiatry

Maimonides Medical Center Brooklyn, New York Thomas R. Kosten, MD

David Juurlink, MD, PhD

Waggoner Chair and Professor of Psychiatry,

Neuroscience, Pharmacology Baylor College of Medicine, Micheal E DeBakey VAMC

Houston, Texas

Kurt Kroenke, MD

Professor of Medicine, Indiana University Research Scientist, VA HSR&D Center for Implementing Evidence-Based Practice, Regenstrief Institute Indianapolis, Indiana Eric B. Larson, MD, MPH

Vice President for Research, Group Health Exec. Director, Group Health Research Institute

Seattle, Washington

Petros Levounis, MD, MA

Director, The Addiction Institute of New York Associate Chair for Clinical Services, Dept. of Psychiatry, St. Luke's & Roosevelt Hospitals New York, New York Elinore F. McCance-Katz, MD, PhD Professor, Department of Psychiatry

University of California San Francisco

San Francisco, California

Lewis Nelson, MD

Associate Professor, Dept. of Emergency Medicine New York University School of Medicine

New York, New York

Rosemary Orr, MD

Professor of Anesthesiology, Seattle Children's Hospital and University of Washington

Seattle, Washington

William Phillips, MD, MPH, FAAP Theodore J. Phillips Endowed Professor in Family Medicine, University of Washington

Seattle, Washington

Roger Rosenblatt, MD, MPH, MFR

Professor & Vice Chair, Dept. of Family Medicine University of Washington School of Medicine Seattle, Washington

Harris Silver, MD

Policy Analyst, Senate Memorial 18 New Mexico Drug Policy Task Force, Robert Wood Johnson Foundation Center for Health Policy University of New Mexico

on Streltzer, MD

Program Director, Addiction Psychiatry Professor of Psychiatry, University of Hawaii Honolulu, Hawaii

Barbara J. Turner MD, MSED, MA, MACP Professor of Medicine; Director, ReACH Center Director, Health Outcomes Improvement University of Texas Health Science Center San Antonio, Texas

Michael Von Korff, ScD

Senior Investigator

Group Health Research Institute

Seattle, Washington

Stone Mountain Health Services

St. Charles Clinic Charles, Virginia Charles Reznikoff, MD

Internal Medicine and Addiction Medicine,

Hennepin County Medical Center

Minneapolis, Minnesota

Nirav R. Shah, MD, MPH

Commissioner

New York State Department of Health Albany, New York

Kurt C. Stange, MD, PhD

Professor of Family Medicine & Community Health, Epidemiology & Biostatistics, Oncology and Sociology, Case Western Reserve University Cleveland, Ohio

Mark Sullivan, MD, PhD

Professor, Dept. of Psychiatry and Behavioral Sciences; Adjunct Professor Bioethics and Humanities; Adjunct Professor, Anesthesiology and Pain Medicine University of Washington Seattle, Washington

Judiel A. Furner

Julenth Turner, PhD

Professor, University of Washington, Dept. of Psychiatry and Behavioral Sciences

Sidney M. Wolfe, MD

Director

Public Citizen's Health Research Group

Washington, DC

REFERENCES

- 1. Centers for Disease Control (CDC). Poison Issue Brief: Unintentional Drug Poisoning in the United States, 2007. Available online at http://www.cdc.gov/HomeandRecreationalSafety/pdf/poision-issue-brief.pdf
- 2. Agency Medical Directors' Group. Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain. Washington State Agency Medical Directors' Group: 2010. Available online at http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf
- 3. Paone D, Dowell D, Heller D. Preventing misuse of prescription opioid drugs. City Health Information. 2011;30(4):23-30. Available online at http://www.nyc.gov/html/doh/downloads/pdf/chi/chi30-4.pdf
- 4. Hamburg MA. Innovation, regulation, and the FDA. N Engl J Med 2010;363:2228-2232.
- 5. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. Morbidity and Mortality Weekly Report. 2011 Nov 1; 60:1-6.
- 6. U.S. General Accounting Office: Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem (GAO-04–110), Washington, DC, U.S. General Accounting Office, 2004
- 7. Van Zee A. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health 2009;99:221–7.
- 8. Suffolk County Supreme Court Special Grand Jury. Grand Jury Report: CPL 190.85(1)(C): April 2012. Available online:
- $\frac{http://www.suffolkcountyny.gov/Portals/da/PDFs/webdoc/diversion\%20 and \%20 dissemination\%20 of \%20 controlled\%20 substances.pdf$
- 9. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C; American Pain Society American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic non-cancer pain. J Pain 2009; 10:113-130.
- 10. Sullivan MD, Von Korff M, Banta-Green C, Merrill JO, Saunders K. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010 May;149(2):345-53.
- 11. Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain. An epidemiological study. Pain 2006;125:172-9.
- 12. Boscarino JA, Rutstalis M, Hoffman SN, Han JJ, Erlich PM, Gerhard GS, Stewart WF. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system Addiction 2010; 105:1776-1782.
- 13. Boscarino JA, Rukstalis MR, Hoffman SN, et al. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 vs. DSM-4 diagnostic criteria. J Addict Dis. 2011;30:185-194.
- 14. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011;26(12):1450-1457.

- 15. Edlund MJ, Fan MY, DeVries A, Braden JB, Martin BC, Sullivan MD. Trends in use of opioids for chronic non-cancer pain among individuals with mental health and substance use disorders: the TROUP Study. Clin J Pain 2010;26:1-8.
- 16. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Annals of Internal Medicine 2010;152:85-92.
- 17. Bohnert AS, Valenstein M, Bair MJ, et al. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA, 305:1315-21.
- 18. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171: 686–91.
- 19. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170:1425-32.
- 20. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 2010;25:310-5.